2023-509900-14-00CompletedPhase 1
A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 7 Aug 2024
- Start date
- 10 Dec 2024
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Alzheimer disease
- EU CT number
- 2023-509900-14-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stichting Amsterdam UMC | Amsterdam | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.